Evidence map›Paper›PMID 42192947›Full record

ArticleCancers2026

Organoid Level Assessments of Human Primary and Metastatic Colorectal Cancer-Derived Organoids Predict Response to Chemotherapy and Chemoradiation.

Shirsa Udgata, Alexa E Schmitz, Amani A Gillette, Alexandra G Sorenson, Jeremiah M Riendeau, Rian Engeldinger, Jordan N Stoecker, Alyssa K Steimle, Katherine A Johnson, Devan Kittelson and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Shirsa UdgataDivision of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, USA.ORCID 0000-0002-1929-8121
Alexa E SchmitzDivision of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, USA.
Amani A GilletteMorgridge Institute for Research, Madison, WI 53715, USA.
Alexandra G SorensonMorgridge Institute for Research, Madison, WI 53715, USA.
Jeremiah M RiendeauDepartment of Biomedical Engineering, University of Wisconsin-Madison, Madison, WI 53705, USA.
Rian EngeldingerDivision of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, USA.
Jordan N StoeckerDivision of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, USA.
Alyssa K SteimleDivision of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, USA.ORCID 0009-0003-1932-0338
Katherine A JohnsonDivision of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, USA.ORCID 0000-0002-6335-7782
Devan KittelsonSchool of Computer, Data, and Information Sciences, University of Wisconsin-Madison, Madison, WI 53705, USA.
Alexandra IsaakMorgridge Institute for Research, Madison, WI 53715, USA.
Jeremy D KratzDivision of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, USA.ORCID 0000-0003-1979-3955
Evie CarchmanUniversity of Wisconsin Carbone Cancer Center, Madison, WI 53705, USA.ORCID 0000-0002-5536-7761
Randall KimpleUniversity of Wisconsin Carbone Cancer Center, Madison, WI 53705, USA.
Cheri A PaschDivision of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, USA.ORCID 0009-0005-9683-7378
Melissa C SkalaMorgridge Institute for Research, Madison, WI 53715, USA.ORCID 0000-0002-6320-7637
Dustin A DemingDivision of Hematology, Medical Oncology, and Palliative Care, Department of Medicine, University of Wisconsin School of Medicine and Public Health, University of Wisconsin-Madison, Madison, WI 53705, USA.

Funding

UW COMPREHENSIVE CANCER CENTER SUPPORTP30CA014520 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI AMY TRENTHAM-DIETZ · 1985 to 2026
$142.6M
Optical imaging to predict cell-level genetic heterogeneity and treatment sensitivity in colorectal cancerR37CA226526 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI DEMING, DUSTIN A · 2018 to 2024
$4.2M
Functional optical imaging for rapid, label-free predictions of treatment response and clonal evolution in patient-derived cancer organoidsR01CA272855 · NCI · MORGRIDGE INSTITUTE FOR RESEARCH, INC. · PI Dustin A Deming, Melissa Caroline Skala · 2023 to 2026
$3.1M
Label-free imaging of CAR T cell metabolismR01CA278051 · NCI · MORGRIDGE INSTITUTE FOR RESEARCH, INC. · PI Christian Capitini, Krishanu Saha · 2023 to 2026
$2.6M
Label-free single-cell imaging for quality control of cardiomyocyte biomanufacturingR01HL165726 · NHLBI · MORGRIDGE INSTITUTE FOR RESEARCH, INC. · PI Sean P Palecek, Melissa Caroline Skala · 2023 to 2026
$2.5M
ACI/Schwenn Family Professorship N/ACathy Wingert Colorectal Cancer Research Fund N/AFunk Out Cancer N/AJD Fluno Family Colon Cancer Precision Medicine Program N/ANCI NIH HHS P30 CA014520NCI NIH HHS R01 CA272855NCI NIH HHS R01 CA278051NCI NIH HHS R37 CA226526NHLBI NIH HHS R01 HL165726NIH HHS P30CA014520NIH HHS R01CA272855NIH HHS R01CA278051NIH HHS R01HL165726NIH HHS R37CA226526
6 · The paper itself

Abstract

backgroundTherapies for metastatic colorectal cancer (CRC) are largely chosen without considering inter-patient heterogeneity, leading to unnecessary side effects without clinical benefit for some patients. Patient-derived cancer organoids (PDCOs) faithfully recapitulate the morphology and molecular profiles of the primary tumors from which they are derived, making them attractive preclinical models for predicting response to standard therapies, and thus, for use in drug development assays.

methodsHere, we investigate the hidden subclonal driver mutations in CRC PDCOs and the importance of individual PDCO-level heterogeneity when addressing PDCO treatment responses using changes in diameter and optical redox imaging. PDCO response is then compared to clinical response across a cohort of subjects with CRC receiving chemotherapy and/or chemoradiation.

resultsChange in diameter and optical redox imaging are more sensitive to detecting therapeutic response than endpoint and well-level measurements. These measurements accurately reflect clinical responses to chemotherapy and chemoradiation.

conclusionsOverall, these studies demonstrate the importance of PDCO-level methods of PDCO assessment and further establish PDCOs as powerful tools for drug response assessment and developmental therapeutic studies.

Indexed as

colorectal canceroptical redox imagingorganoidspatient-derived cancer organoidspreclinical cancer models

Identifiers

PMID42192947
PMCPMC13205027

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.